HCV ADVOCATE WEEKLY NEWS REVIEW

[Guest guest]

HCV ADVOCATE WEEKLY NEWS REVIEW

This Issue:

Enzyme Deficiency Protects Hepatitis C Patients from Treatment-Related Anemia Hepatitis C Virus Can Survive in Syringes for up to 63 Days CROI: HCV Therapy Response Predicts Outcome in Co-Infected Patients Dying Prisoner with Liver Disease, Mass in Abdomen Has Gone Months without Medical Care Six Year Wait List for Hep C Treatment Histostem Participates in Clinical Trials Demonstrating the Effective Use of Its Proprietary Stem Cells in the Treatment of Cirrhosis of the Liver UPDATE 2-US Panel Backs Salix Antibiotic for Liver Disorder Ocera Therapeutics Completes Phase 2B Enrollment in the ASTUTE Trial Mouse Gets Human Liver Hepatitis B and C Remain Public Health Issue – Up to 5.3 Million Americans Infected Eisai Launches REVOVIR® in the Philippines for the Treatment of Chronic Hepatitis B UPDATE 2-Anadys Hep C Drug Shows Early 73 Pct Response-Study Regulus Therapeutics and GlaxoKline Establish New Collaboration to Develop and Commercialize microRNA Therapeutics Targeting miR-122 Phones, Paper 'Chips' May Fight Disease More Reliable Biomarkers Needed for Early Detection of Liver Cancer 30 Years for Surgical Tech in Hepatitis C Outbreak Doctor in Hepatitis Case Surrenders License Avila Aims to Trump Vertex with Drug that Hits Hepatitis C Virus and Won’t Let Go HIV, HIV/HCV Coinfection Double the Risk for Stroke

http://www.hcvadvocate.org/news/newsRev/2010/NewsRev-350.html